Currently, Immunome Inc [IMNM] is trading at $14.62, up 2.81%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMNM shares have gain 5.94% over the last week, with a monthly amount glided 6.48%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on April 30, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $24. Previously, Guggenheim started tracking the stock with Buy rating on April 15, 2024, and set its price target to $35. On January 29, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $30 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $12 on December 19, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $35 as its price target on October 29, 2021.
This stock has fluctuated between a low of $4.50 and a high of $30.96 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $14.62 at the most recent close of the market. An investor can expect a potential return of 132.56% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Trailing Twelve Months sales for Immunome Inc [NASDAQ:IMNM] were 12.68M which represents -56.47% decline. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -18.71%, Pretax Profit Margin comes in at -18.29%, and Net Profit Margin reading is -18.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -2.21 and Total Capital is -0.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.24 points at the first support level, and at 13.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.99, and for the 2nd resistance point, it is at 15.37.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunome Inc [NASDAQ:IMNM] is 10.18. Also, the Quick Ratio is 10.18, while the Cash Ratio stands at 8.77. Considering the valuation of this stock, the price to sales ratio is 69.15, the price to book ratio is 3.06.
Transactions by insiders
Recent insider trading involved SIEGALL CLAY B, President and CEO, that happened on May 21 ’24 when 20434.0 shares were purchased. Director, BIENAIME JEAN JACQUES completed a deal on May 21 ’24 to buy 2000.0 shares. Meanwhile, President and CEO SIEGALL CLAY B bought 79566.0 shares on May 20 ’24.
